财中社1月24日电昭衍新药(603127/06127)发布公告,预计2024年实现营业收入约19.17亿元到21.19亿元,与上年同期相比将减少约2.57亿元到4.59亿元,同比下降约10.8%到19.3%。同时,归母净利润预计约为5869万元到8803万元,较上年同期减少约3.09亿元到3.38亿元,同比下降约77.8%到85.2%。归母净利润扣除非经常性损益后预计约为1789万元到2684万元...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.